{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["apoptosis", "breast cancer", "cell migration", "cell viability", "natural compounds"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "31963771", "DateCompleted": {"Year": "2021", "Month": "03", "Day": "15"}, "DateRevised": {"Year": "2021", "Month": "03", "Day": "15"}, "Article": {"ArticleDate": [{"Year": "2020", "Month": "01", "Day": "19"}], "Language": ["eng"], "ELocationID": ["158", "10.3390/biom10010158"], "Journal": {"ISSN": "2218-273X", "JournalIssue": {"Volume": "10", "Issue": "1", "PubDate": {"Year": "2020", "Month": "Jan", "Day": "19"}}, "Title": "Biomolecules", "ISOAbbreviation": "Biomolecules"}, "ArticleTitle": "Anti-Migratory and Pro-Apoptotic Properties of Parvifloron D on Triple-Negative Breast Cancer Cells.", "Abstract": {"AbstractText": ["Medicinal plants are important sources of new bioactive compounds with potential anticancer activity. Parvifloron D (ParvD) is an abietane diterpenoid, isolated in high amounts from <i>Plectranthus ecklonii</i> Benth. Previous reports have suggested potential therapeutic properties for ParvD. ParvD has shown pro-apoptotic and cytotoxic effects in leukemia and melanoma cell lines. However, to the best of our knowledge, there are no studies in triple-negative breast cancer (TNBC) models. TNBC is a breast cancer subtype characterized by an aggressive behavior with poor clinical outcomes and weak overall therapeutic responses to the current treatment options. This work aimed at evaluating the anticancer effect of ParvD in MDA-MB-231 cells, a model of human TNBC. To obtain sufficient amounts of purified ParvD the efficiency of several extraction methods was compared. ParvD (0.1-10 \u00b5M) decreased cell viability in a concentration-dependent manner. Treatment with ParvD (5 \u00b5M) significantly increased the percentage of apoptotic nuclei and exposure to 3 \u00b5M ParvD increased the sub-G1 population. Since altered cell adherence, migration, and invasion are determinant processes for the formation of metastases, the effect of ParvD on these cellular processes was tested. Although treatment with ParvD (1 \u00b5M) had no effect on cell-substrate attachment, ParvD (1 \u00b5M) significantly reduced cell chemotaxis and invasion. This is the first report describing the proapoptotic effect of ParvD in TNBC cells. Moreover, for the first time we have shown that ParvD reduces cell motility, unraveling potential anti-metastatic properties."]}, "AuthorList": [{"Identifier": ["0000-0003-1333-9137"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "CBIOS, Universidade Lus\u00f3fona Research Center for Biosciences & Health Technologies, Campo Grande 376, 1749-024 Lisboa, Portugal."}], "LastName": "Saraiva", "ForeName": "Nuno", "Initials": "N"}, {"Identifier": ["0000-0002-5604-6142"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "CBIOS, Universidade Lus\u00f3fona Research Center for Biosciences & Health Technologies, Campo Grande 376, 1749-024 Lisboa, Portugal."}, {"Identifier": [], "Affiliation": "Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Professor Gama Pinto, 1649-003 Lisboa, Portugal."}], "LastName": "Costa", "ForeName": "Jo\u00e3o G", "Initials": "JG"}, {"Identifier": ["0000-0002-1046-4031"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "CBIOS, Universidade Lus\u00f3fona Research Center for Biosciences & Health Technologies, Campo Grande 376, 1749-024 Lisboa, Portugal."}, {"Identifier": [], "Affiliation": "Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Professor Gama Pinto, 1649-003 Lisboa, Portugal."}], "LastName": "Reis", "ForeName": "Catarina", "Initials": "C"}, {"Identifier": ["0000-0001-7768-244X"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "CBIOS, Universidade Lus\u00f3fona Research Center for Biosciences & Health Technologies, Campo Grande 376, 1749-024 Lisboa, Portugal."}], "LastName": "Almeida", "ForeName": "Nuno", "Initials": "N"}, {"Identifier": ["0000-0001-7992-8343"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "CBIOS, Universidade Lus\u00f3fona Research Center for Biosciences & Health Technologies, Campo Grande 376, 1749-024 Lisboa, Portugal."}, {"Identifier": [], "Affiliation": "Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Professor Gama Pinto, 1649-003 Lisboa, Portugal."}], "LastName": "Rijo", "ForeName": "Patr\u00edcia", "Initials": "P"}, {"Identifier": ["0000-0001-6350-0641"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "CBIOS, Universidade Lus\u00f3fona Research Center for Biosciences & Health Technologies, Campo Grande 376, 1749-024 Lisboa, Portugal."}], "LastName": "Fernandes", "ForeName": "Ana Sofia", "Initials": "AS"}], "GrantList": [{"GrantID": "UID/DTP/04567/2016", "Agency": "Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia", "Country": "International"}, {"GrantID": "UID/DTP/04567/2019", "Agency": "Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia", "Country": "International"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Biomolecules", "NlmUniqueID": "101596414", "ISSNLinking": "2218-273X"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "2-(4-hydroxy)-benzoyloxy-11-hydroxy-5,7,9(11),13-abietatetraen-12-one"}, {"RegistryNumber": "0", "NameOfSubstance": "Abietanes"}, {"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents, Phytogenic"}], "MeshHeadingList": [{"QualifierName": ["isolation & purification", "pharmacology"], "DescriptorName": "Abietanes"}, {"QualifierName": ["isolation & purification", "pharmacology"], "DescriptorName": "Antineoplastic Agents, Phytogenic"}, {"QualifierName": ["drug effects"], "DescriptorName": "Apoptosis"}, {"QualifierName": [], "DescriptorName": "Cell Line, Tumor"}, {"QualifierName": ["drug effects"], "DescriptorName": "Cell Movement"}, {"QualifierName": ["drug effects"], "DescriptorName": "Cell Proliferation"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["chemistry"], "DescriptorName": "Plectranthus"}, {"QualifierName": ["drug therapy", "metabolism", "pathology"], "DescriptorName": "Triple Negative Breast Neoplasms"}], "CoiStatement": "The authors declare that there is no conflict of interest regarding the publication of this paper."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Nahata A. Anticancer Agents: A Review of Relevant Information on Important Herbal Drugs. Int. J. Clin. Pharmacol. Toxicol. 2017;6:250\u2013255. doi: 10.19070/2167-910x-1700042.", "ArticleIdList": ["10.19070/2167-910x-1700042"]}, {"Citation": "Vallejo M.J., Salazar L., Grijalva M. Oxidative Stress Modulation and ROS-Mediated Toxicity in Cancer: A Review on. Oxid. Med. Cell. Longev. 2017;2017:4586068. doi: 10.1155/2017/4586068.", "ArticleIdList": ["10.1155/2017/4586068", "PMC5674509", "29204247"]}, {"Citation": "Greenwell M., Rahman P.K. Medicinal Plants: Their Use in Anticancer Treatment. Int. J. Pharm. Sci. Res. 2015;6:4103\u20134112. doi: 10.13040/IJPSR.0975-8232.6(10).4103-12.", "ArticleIdList": ["10.13040/IJPSR.0975-8232.6(10).4103-12", "PMC4650206", "26594645"]}, {"Citation": "Wallace D. Natural Products as a Source of Anti-Cancer Lead Compounds: Ginger and Breast Cancer. J. Pharm. Clin. Res. 2016;1:1\u20136. doi: 10.19080/JPCR.2016.01.555564.", "ArticleIdList": ["10.19080/JPCR.2016.01.555564"]}, {"Citation": "Lukhoba C.W., Simmonds M.S., Paton A.J. Plectranthus: A review of ethnobotanical uses. J. Ethnopharmacol. 2006;103:1\u201324. doi: 10.1016/j.jep.2005.09.011.", "ArticleIdList": ["10.1016/j.jep.2005.09.011", "16289602"]}, {"Citation": "Figueiredo N. Phytochemical Analysis of Plectranthus sp. Extracts and Application in Inhibition of Dental Bacteria, Streptococcus sobrinus and Streptococcus mutans. Eur. J. Med. Plants. 2014;4:794\u2013809. doi: 10.9734/EJMP/2014/7544.", "ArticleIdList": ["10.9734/EJMP/2014/7544"]}, {"Citation": "Burmistrova O., Perdomo J., Sim\u00f5es M.F., Rijo P., Quintana J., Est\u00e9vez F. The abietane diterpenoid parvifloron D from Plectranthus ecklonii is a potent apoptotic inducer in human leukemia cells. Phytomedicine. 2015;22:1009\u20131016. doi: 10.1016/j.phymed.2015.06.013.", "ArticleIdList": ["10.1016/j.phymed.2015.06.013", "26407943"]}, {"Citation": "Garcia C., Teod\u00f3sio C., Oliveira C., D\u00edaz-Lanza A., Reis C., Duarte N., Rijo P. Naturally Occurring Plectranthus-derived Diterpenes with Antitumoral Activities. Curr. Pharm. Des. 2018;24:4207\u20134236. doi: 10.2174/1381612825666190115144241.", "ArticleIdList": ["10.2174/1381612825666190115144241", "30644340"]}, {"Citation": "Matias D., Nicolai M., Fernandes A.S., Saraiva N., Almeida J., Saraiva L., Faustino C., D\u00edaz-Lanza A.M., Reis C.P., Rijo P. Comparison Study of Different Extracts of Plectranthus madagascariensis, P. neochilus and the Rare, P. porcatus (Lamiaceae): Chemical Characterization, Antioxidant, Antimicrobial and Cytotoxic Activities. Biomolecules. 2019;9:179. doi: 10.3390/biom9050179.", "ArticleIdList": ["10.3390/biom9050179", "PMC6571840", "31072074"]}, {"Citation": "Matias D., Nicolai M., Saraiva L., Pinheiro R., Faustino C., Diaz Lanza A., Pinto Reis C., Stankovic T., Dinic J., Pesic M., et al. Cytotoxic Activity of Royleanone Diterpenes from Plectranthus madagascariensis Benth. ACS Omega. 2019;4:8094\u20138103. doi: 10.1021/acsomega.9b00512.", "ArticleIdList": ["10.1021/acsomega.9b00512", "PMC6648853", "31459900"]}, {"Citation": "Sim\u00f5es M.F., Rijo P., Duarte A., Matias D., Rodr\u00edguez B. An easy and stereoselective rearrangement of an abietane diterpenoid into a bioactive microstegiol derivative. Phytochem. Lett. 2010;3:234\u2013237. doi: 10.1016/j.phytol.2010.09.001.", "ArticleIdList": ["10.1016/j.phytol.2010.09.001"]}, {"Citation": "Silva C.O., Molpeceres J., Batanero B., Fernandes A.S., Saraiva N., Costa J.G., Rijo P., Figueiredo I.V., Fa\u00edsca P., Reis C.P. Functionalized diterpene parvifloron D-loaded hybrid nanoparticles for targeted delivery in melanoma therapy. Ther. Deliv. 2016;7:521\u2013544. doi: 10.4155/tde-2016-0027.", "ArticleIdList": ["10.4155/tde-2016-0027", "27444493"]}, {"Citation": "Santos-Rebelo A., Garcia C., Eleut\u00e9rio C., Bastos A., Coelho S.C., Coelho M.A.N., Molpeceres J., Viana A.S., Ascens\u00e3o L., Pinto J.F., et al. Development of Parvifloron D-loaded Smart Nanoparticles to Target Pancreatic Cancer. Pharmaceutics. 2018;10:216. doi: 10.3390/pharmaceutics10040216.", "ArticleIdList": ["10.3390/pharmaceutics10040216", "PMC6321128", "30400382"]}, {"Citation": "Cetin I., Topcul M. Triple negative breast cancer. Asian Pac. J. Cancer Prev. 2014;15:2427\u20132431. doi: 10.7314/APJCP.2014.15.6.2427.", "ArticleIdList": ["10.7314/APJCP.2014.15.6.2427", "24761842"]}, {"Citation": "Foulkes W.D., Smith I.E., Reis-Filho J.S. Triple-negative breast cancer. N. Engl. J. Med. 2010;363:1938\u20131948. doi: 10.1056/NEJMra1001389.", "ArticleIdList": ["10.1056/NEJMra1001389", "21067385"]}, {"Citation": "Avery T.P. Changing Paradigms in the Management of Breast Cancer. Springer International Publishing; Manhattan, NY, USA: 2017. Triple-Negative Breast Cancer; pp. 155\u2013166."}, {"Citation": "Costa R.L.B., Han H.S., Gradishar W.J. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: A review. Breast Cancer Res. Treat. 2018;169:397\u2013406. doi: 10.1007/s10549-018-4697-y.", "ArticleIdList": ["10.1007/s10549-018-4697-y", "29417298"]}, {"Citation": "Lehmann B.D., Bauer J.A., Chen X., Sanders M.E., Chakravarthy A.B., Shyr Y., Pietenpol J.A. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Investig. 2011;121:2750\u20132767. doi: 10.1172/JCI45014.", "ArticleIdList": ["10.1172/JCI45014", "PMC3127435", "21633166"]}, {"Citation": "Hudis C.A., Gianni L. Triple-Negative Breast Cancer: An Unmet Medical Need. Oncologist. 2011;16:1\u201311. doi: 10.1634/theoncologist.2011-S1-01.", "ArticleIdList": ["10.1634/theoncologist.2011-S1-01", "21278435"]}, {"Citation": "Bernardes C.E.S., Garcia C., Pereira F., Mota J., Pereira P., Cebola M.J., Reis C.P., Correia I., Piedade M.F.M., Minas da Piedade M.E., et al. Extraction Optimization and Structural and Thermal Characterization of the Antimicrobial Abietane 7\u03b1-Acetoxy-6\u03b2-hydroxyroyleanone. Mol. Pharm. 2018;15:1412\u20131419. doi: 10.1021/acs.molpharmaceut.7b00892.", "ArticleIdList": ["10.1021/acs.molpharmaceut.7b00892", "29494159"]}, {"Citation": "Fl\u00f3rido A., Saraiva N., Cerqueira S., Almeida N., Parsons M., Batinic-Haberle I., Miranda J.P., Costa J.G., Carrara G., Castro M., et al. The manganese(III) porphyrin MnTnHex-2-PyP(5+) modulates intracellular ROS and breast cancer cell migration: Impact on doxorubicin-treated cells. Redox Biol. 2019;20:367\u2013378. doi: 10.1016/j.redox.2018.10.016.", "ArticleIdList": ["10.1016/j.redox.2018.10.016", "PMC6222139", "30408752"]}, {"Citation": "Fernandes A.S., Gaspar J., Cabral M.F., Rueff J., Castro M., Batinic-Haberle I., Costa J., Oliveira N.G. Protective role of ortho-substituted Mn(III) N-alkylpyridylporphyrins against the oxidative injury induced by tert-butylhydroperoxide. Free Radic. Res. 2010;44:430\u2013440. doi: 10.3109/10715760903555844.", "ArticleIdList": ["10.3109/10715760903555844", "20102317"]}, {"Citation": "Caparica R., J\u00falio A., Baby A.R., Ara\u00fajo M.E.M., Fernandes A.S., Costa J.G., Santos de Almeida T. Choline-Amino Acid Ionic Liquids as Green Functional Excipients to Enhance Drug Solubility. Pharmaceutics. 2018;10:288. doi: 10.3390/pharmaceutics10040288.", "ArticleIdList": ["10.3390/pharmaceutics10040288", "PMC6321021", "30572636"]}, {"Citation": "Costa J.G., Saraiva N., Batinic-Haberle I., Castro M., Oliveira N.G., Fernandes A.S. The SOD Mimic MnTnHex-2-PyP(5+) reduces the viability and migration of 786-O human renal cancer cells. Antioxidants. 2019;8:490. doi: 10.3390/antiox8100490.", "ArticleIdList": ["10.3390/antiox8100490", "PMC6826590", "31627290"]}, {"Citation": "Chazotte B. Labeling nuclear DNA using DAPI. Cold Spring Harb. Protoc. 2011;2011:pdb.prot5556. doi: 10.1101/pdb.prot5556.", "ArticleIdList": ["10.1101/pdb.prot5556", "21205856"]}, {"Citation": "Costa J.G., Saraiva N., Guerreiro P.S., Louro H., Silva M.J., Miranda J.P., Castro M., Batinic-Haberle I., Fernandes A.S., Oliveira N.G. Ochratoxin A-induced cytotoxicity, genotoxicity and reactive oxygen species in kidney cells: An integrative approach of complementary endpoints. Food Chem. Toxicol. 2016;87:65\u201376. doi: 10.1016/j.fct.2015.11.018.", "ArticleIdList": ["10.1016/j.fct.2015.11.018", "26627377"]}, {"Citation": "Guerreiro P.S., Corvacho E., Costa J.G., Saraiva N., Fernandes A.S., Castro M., Miranda J.P., Oliveira N.G. The APE1 redox inhibitor E3330 reduces collective cell migration of human breast cancer cells and decreases chemoinvasion and colony formation when combined with docetaxel. Chem. Biol. Drug Des. 2017;90:561\u2013571. doi: 10.1111/cbdd.12979.", "ArticleIdList": ["10.1111/cbdd.12979", "28303665"]}, {"Citation": "Fernandes A.S., Fl\u00f3rido A., Saraiva N., Cerqueira S., Ramalhete S., Cipriano M., Cabral M.F., Miranda J.P., Castro M., Costa J., et al. Role of the Copper(II) Complex Cu[15]pyN5 in Intracellular ROS and Breast Cancer Cell Motility and Invasion. Chem. Biol. Drug Des. 2015;86:578\u2013588. doi: 10.1111/cbdd.12521.", "ArticleIdList": ["10.1111/cbdd.12521", "25600158"]}, {"Citation": "Saraiva N., Prole D.L., Carrara G., Johnson B.F., Taylor C.W., Parsons M., Smith G.L. hGAAP promotes cell adhesion and migration via the stimulation of store-operated Ca2+ entry and calpain 2. J. Cell. Biol. 2013;202:699\u2013713. doi: 10.1083/jcb.201301016.", "ArticleIdList": ["10.1083/jcb.201301016", "PMC3747308", "23940116"]}, {"Citation": "Rijo P., Fal\u00e9 P.L., Serralheiro M.L., Sim\u00f5es M.F., Gomes A., Reis C. Optimization of medicinal plant extraction methods and their encapsulation through extrusion technology. Measurement. 2014;58:249\u2013255. doi: 10.1016/j.measurement.2014.08.045.", "ArticleIdList": ["10.1016/j.measurement.2014.08.045"]}, {"Citation": "Chen J., Lu L., Feng Y., Wang H., Dai L., Li Y., Zhang P. PKD2 mediates multi-drug resistance in breast cancer cells through modulation of P-glycoprotein expression. Cancer Lett. 2011;300:48\u201356. doi: 10.1016/j.canlet.2010.09.005.", "ArticleIdList": ["10.1016/j.canlet.2010.09.005", "20934246"]}, {"Citation": "Lee C.L., Chang F.R., Hsieh P.W., Chiang M.Y., Wu C.C., Huang Z.Y., Lan Y.H., Chen M., Lee K.H., Yen H.F., et al. Cytotoxic ent-abietane diterpenes from Gelonium aequoreum. Phytochemistry. 2008;69:276\u2013287. doi: 10.1016/j.phytochem.2007.07.005.", "ArticleIdList": ["10.1016/j.phytochem.2007.07.005", "17714747"]}, {"Citation": "Yang J.C., Lu M.C., Lee C.L., Chen G.Y., Lin Y.Y., Chang F.R., Wu Y.C. Selective targeting of breast cancer cells through ROS-mediated mechanisms potentiates the lethality of paclitaxel by a novel diterpene, gelomulide K. Free Radic. Biol. Med. 2011;51:641\u2013657. doi: 10.1016/j.freeradbiomed.2011.05.012.", "ArticleIdList": ["10.1016/j.freeradbiomed.2011.05.012", "21641992"]}, {"Citation": "Song J.T., Han Y., Wang X.L., Shen T., Lou H.X., Wang X.N. Diterpenoids from the twigs and leaves of Croton caudatus var. tomentosus. Fitoterapia. 2015;107:54\u201359. doi: 10.1016/j.fitote.2015.10.006.", "ArticleIdList": ["10.1016/j.fitote.2015.10.006", "26475984"]}, {"Citation": "Illiano M., Sapio L., Salzillo A., Capasso L., Caiafa I., Chiosi E., Spina A., Naviglio S. Forskolin improves sensitivity to doxorubicin of triple negative breast cancer cells via Protein Kinase A-mediated ERK1/2 inhibition. Biochem. Pharmacol. 2018;152:104\u2013113. doi: 10.1016/j.bcp.2018.03.023.", "ArticleIdList": ["10.1016/j.bcp.2018.03.023", "29574069"]}, {"Citation": "Inao T., Iida Y., Moritani T., Okimoto T., Tanino R., Kotani H., Harada M. Bcl-2 inhibition sensitizes triple-negative human breast cancer cells to doxorubicin. Oncotarget. 2018;9:25545\u201325556. doi: 10.18632/oncotarget.25370.", "ArticleIdList": ["10.18632/oncotarget.25370", "PMC5986635", "29876007"]}, {"Citation": "Al-Mahmood S., Sapiezynski J., Garbuzenko O.B., Minko T. Metastatic and triple-negative breast cancer: Challenges and treatment options. Drug Deliv. Transl. Res. 2018;8:1483\u20131507. doi: 10.1007/s13346-018-0551-3.", "ArticleIdList": ["10.1007/s13346-018-0551-3", "PMC6133085", "29978332"]}, {"Citation": "Roussos E.T., Condeelis J.S., Patsialou A. Chemotaxis in cancer. Nat. Rev. Cancer. 2011;11:573\u2013587. doi: 10.1038/nrc3078.", "ArticleIdList": ["10.1038/nrc3078", "PMC4030706", "21779009"]}, {"Citation": "Razak N.A., Abu N., Ho W.Y., Zamberi N.R., Rizi N., Tan S.W., Alitheen N.B., Banu N., Long K., Yeap S.K. Cytotoxicity of eupatorin in MCF-7 and MDA-MB-231 human breast cancer cells via cell cycle arrest, anti-angiogenesis and induction of apoptosis. Sci. Rep. 2019;9:1514. doi: 10.1038/s41598-018-37796-w.", "ArticleIdList": ["10.1038/s41598-018-37796-w", "PMC6365513", "30728391"]}, {"Citation": "Takeshita T., Wu W., Koike A., Fukuda M., Ohta T. Perturbation of DNA repair pathways by proteasome inhibitors corresponds to enhanced chemosensitivity of cells to DNA damage-inducing agents. Cancer Chemother. Pharmacol. 2009;64:1039\u20131046. doi: 10.1007/s00280-009-0961-5.", "ArticleIdList": ["10.1007/s00280-009-0961-5", "PMC2728221", "19274461"]}]}], "History": [{"Year": "2019", "Month": "12", "Day": "19"}, {"Year": "2020", "Month": "1", "Day": "9"}, {"Year": "2020", "Month": "1", "Day": "10"}, {"Year": "2020", "Month": "1", "Day": "23", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "1", "Day": "23", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "3", "Day": "16", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "1", "Day": "1"}], "PublicationStatus": "epublish", "ArticleIdList": ["31963771", "PMC7023143", "10.3390/biom10010158", "biom10010158"]}}]}